Compare Summit Therapeutics Inc (SMMT) vs Vanguard Ultra Short Bond ETF (VUSB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Vanguard Ultra Short Bond ETF — how do they compare? Summit Therapeutics Inc trades at $15.1 (market cap $12.06B), while Vanguard Ultra Short Bond ETF trades at $49.69. Which is the better fit depends on your goals.
| SMMT | VUSB | |
|---|---|---|
Market Cap | $12.06B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $26.98 | $50.03 |
52-Week Low | $12.55 | $49.60 |
Enterprise Value | $11.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $15.10, up 1.55% with a bullish technical signal and strong analyst support. The company shows negative profitability metrics with ROE at -192.5% and net income of -$1.08B for 2025, but maintains positive cash flow through financing activities. Recent developments include FDA review of ivonescimab with a November 2026 decision date and expansion into bladder cancer trials, driving investor optimism despite ongoing losses.
The investment case hinges on ivonescimab's regulatory approval potential, with a consensus price target of $27.90 representing 85% upside. Key risks include cash burn concerns, fiduciary duty investigations, and clinical trial outcomes. While fundamentals remain weak, the stock offers high-risk, high-reward potential for speculative biotech investors betting on successful drug commercialization.
VUSB trades at $49.68 with minimal daily movement (+0.04%). The technical picture is bearish with moving averages signaling selling pressure, though oscillators remain neutral. Recent dividend distributions show consistent payouts, with the latest being $0.18 paid on July 6, 2026. Financial ratios are unavailable in the current data snapshot.
The outlook remains cautious due to bearish technical indicators and potential interest rate sensitivity. Recent financial media suggests short-term bond ETFs like VUSB may benefit from Fed rate increases in 2026, though the current technical weakness warrants careful monitoring of support levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Vanguard Ultra Short Bond ETF
VUSB is an actively managed ETF from Vanguard that invests in a diversified portfolio of high-quality, investment-grade fixed income securities with maturities typically under two years. It is designed to offer higher yield potential than traditional money market funds while maintaining limited price volatility, making it a strategic tool for managing short-term reserves with a 6-to-18-month horizon.
Read more on VUSB →
